Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 4/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.50 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.50 |
| ▸ | RET | P07949 | 7/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.31 |
| ▸ | GNRHR | P30968 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4906666 | 0.91 | RXRA (0.53) | RXRANR1H2NR1H3RETRXRB | |
| SCHEMBL4906136 | 0.89 | RXRA (0.56) | RXRANR1H2NR1H3RETRXRB | |
| SCHEMBL2390458 | 0.89 | RXRA (0.56) | RXRANR1H2NR1H3RETRXRB | |
| SCHEMBL4908315 | 0.87 | RXRA (0.58) | RXRANR1H2NR1H3RETRXRB | |
| SCHEMBL4897154 | 0.87 | RXRA (0.50) | RXRANR1H2NR1H3RETRXRB | |
| SCHEMBL2387731 | 0.86 | RXRA (0.55) | RXRANR1H2NR1H3RET | |
| SCHEMBL2390524 | 0.86 | RXRA (0.56) | RXRANR1H2NR1H3RETMAPT | |
| SCHEMBL2390102 | 0.85 | RXRA (0.54) | RXRANR1H2NR1H3RETMAPT | |
| SCHEMBL2389141 | 0.85 | RXRA (0.54) | RXRANR1H2NR1H3RETMAPT | |
| SCHEMBL2388279 | 0.84 | RXRA (0.48) | RXRANR1H2NR1H3RETMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119488-A1 | Modulators Of Nuclear Receptors | NR1H2, NR0B1, NR1H3 | RXRA 20/4885NR1H2 1/4885NR1H3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.